USING PRE-CLINICAL EXPERIMENTAL MODELS, GLIOBLASTOMAS TUMORS DISPLAY THERAPEUTIC VULNERABILITY TO PHARMACOLOGIC TREATMENT WITH THE YAP/TAZ INHIBITOR AND PORPHYRIN DERIVATIVE VERTEPORFIN. TESTING OF AN FDA-APPROVED LIPOSOMAL FORMULATION OF VERTEPORFIN IN A PHASE 1/2 CLINICAL TRIALS IN HUMAN GLIOBLASTOMA PATIENTS AND TO IDENTIFY BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSE TO THIS DRUG.